x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011961
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, Flow Cyt |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu734 of human DGKA protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | DGKA |
| UniProt No. | P23743 |
| Gene ID | 1606 |
| Gene Description | Diacylglycerol kinase alpha is a type 1 diacylglycerol kinase that competes with protein kinase C to convert messenger diacylglycerol to phosphatidic acid. Upon activation of this intracellular lipid kinase, DGKA rapidly relocates from the cytosol to the plasma membrane where it is involved in multiple cellular processes, including regulating lipid and glucose metabolism levels, cell growth, and cell signaling. Expression of DGKA is high in T lymphocytes, and detectable in endothelial cells, epithelial cells, fibroblasts, and oligodendrocytes. DGKA negatively regulates T cell receptor-dependent responses through phosphorylation of phospholipase C-derived DAG. In contrast, DGKA-dependent phosphatidic acid generation by phosphorylation of a pre-existing DAG pool is necessary for IL-2-dependent T cell proliferation. DGKA is frequently overexpressed in cancer, promoting tumor cell survival, proliferation, invasion, and metastasis. Due to its role in immunity and cancer, targeting DGKA represents a unique opportunity for therapeutic intervention in cancer. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
